lifestyle.longislandreport.org

Author: UCB, INC.

UCB to acquire Neurona Therapeutics, advancing its innovative leadership in epilepsy through regenerative science

April 17, 2026
UCB presents new data demonstrating quality-of-life impacts for epilepsy patients and caregivers at AAN 2026 meeting

April 15, 2026
UCB announces new clinical data from its generalized myasthenia gravis (gMG) portfolio at the 2026 American Academy of Neurology (AAN) meeting

April 13, 2026
UCB Announces New BIMZELX® (bimekizumab-bkzx) Data at AAD Showing Durable Symptom Control Throughout Three Years in Hidradenitis Suppurativa

March 28, 2026
UCB Announces New BIMZELX® (bimekizumab-bkzx) Data at AAD Showing Durable Symptom Control Throughout Three Years in Hidradenitis Suppurativa

March 27, 2026
UCB Presents New BIMZELX® (bimekizumab-bkzx) Data at AAD Demonstrating High Rates of Durable and Complete Skin Clearance in Moderate-to-Severe Plaque Psoriasis

March 27, 2026
UCB Selects Georgia for New U.S. Biologics Manufacturing Facility; ~$5B Economic Impact and ~330 Permanent Jobs

March 24, 2026
BIMZELX®▼(bimekizumab) superior to SKYRIZI® (risankizumab) in BE BOLD: first head-to-head study in active psoriatic arthritis (PsA) to demonstrate superiority in ACR50

March 11, 2026
BIMZELX® (bimekizumab-bkzx) Data in Hidradenitis Suppurativa Showed Improvements in Pain and Resolution of Draining Tunnels Sustained to Three Years

November 5, 2025
U.S. FDA approves KYGEVVI® (doxecitine and doxribtimine), the first and only treatment for adults and children living with thymidine kinase 2 deficiency (TK2d)

November 4, 2025